key: cord-0742889-8krl5r4l
authors: Cegłowska, Marta; Szubert, Karolina; Grygier, Beata; Lenart, Marzena; Plewka, Jacek; Milewska, Aleksandra; Lis, Kinga; Szczepański, Artur; Chykunova, Yuliya; Barreto-Duran, Emilia; Pyrć, Krzysztof; Kosakowska, Alicja; Mazur-Marzec, Hanna
title: Pseudanabaena galeata CCNP1313—Biological Activity and Peptides Production
date: 2022-05-06
journal: Toxins (Basel)
DOI: 10.3390/toxins14050330
sha: 00335155cac5c2eec377bc7d8147216c79e9e0cf
doc_id: 742889
cord_uid: 8krl5r4l

Even cyanobacteria from ecosystems of low biodiversity, such as the Baltic Sea, can constitute a rich source of bioactive metabolites. Potent toxins, enzyme inhibitors, and anticancer and antifungal agents were detected in both bloom-forming species and less commonly occurring cyanobacteria. In previous work on the Baltic Pseudanabaena galeata CCNP1313, the induction of apoptosis in the breast cancer cell line MCF-7 was documented. Here, the activity of the strain was further explored using human dermal fibroblasts, African green monkey kidney, cancer cell lines (T47D, HCT-8, and A549(ACE2/TMPRSS2)) and viruses (SARS-CoV-2, HCoV-OC43, and WNV). In the tests, extracts, chromatographic fractions, and the main components of the P. galeata CCNP1313 fractions were used. The LC-MS/MS analyses of the tested samples led to the detection of forty-five peptides. For fourteen of the new peptides, putative structures were proposed based on MS/MS spectra. Although the complex samples (i.e., extracts and chromatographic fractions) showed potent cytotoxic and antiviral activities, the effects of the isolated compounds were minor. The study confirmed the significance of P. galeata CCNP1313 as a source of metabolites with potent activity. It also illustrated the difficulties in assigning the observed biological effects to specific metabolites, especially when they are produced in minute amounts.

Cyanobacteria of the genus Pseudanabaena are classified to the Synechococcales order [1] and comprise almost fifty different species [2] . They live in various ecosystems, from marine and freshwater bodies to hot springs, mangrove swamps, and dry steppes [3] [4] [5] [6] [7] [8] [9] [10] . Most of the published works have focused on the taxonomy and the presence of Pseudanabaena in different environments. In some studies, the effects of this cyanobacterium on other aquatic organisms have also been documented [8, 11, 12] . Pseudanabaena extracts were 

First, the activity of the cell extract from P. galeata CCNP1313 (200 µg mL −1 ) was screened using a human breast adenocarcinoma cell line T47D and human dermal fibroblast HDF. The sample reduced the relative viability of T47D cells by 82% (SD = 1), but did not affect the primary HDF (toxicity below 1%). In the second step, the thirty-one flash chromatography fractions (200 µg mL −1 ) obtained from the extract were tested against T47D cells. Twelve of the following fractions reduced the viability of T47D by more than 90%: F40.6-F40.7, F60.6-80.2, and F80.5-80.10 ( Figure 1A) . The same thirty-one fractions were tested against HDF. Eleven of the fractions reduced the cell viability by more than 60%; these were fractions F60.2-F60.5, F60.7-F80.1, and F80.6-F80.10 ( Figure 1B ). did not affect the primary HDF (toxicity below 1%). In the second step, the thirty-one flash chromatography fractions (200 μg mL -1 ) obtained from the extract were tested against T47D cells. Twelve of the following fractions reduced the viability of T47D by more than 90%: F40.6-F40.7, F60.6-80.2, and F80.5-80.10 ( Figure 1A ). The same thirty-one fractions were tested against HDF. Eleven of the fractions reduced the cell viability by more than 60%; these were fractions F60.2-F60.5, F60.7-F80.1, and F80.6-F80.10 ( Figure 1B ). Then, the most active fractions were further separated and the samples with dominant components of the fractions were collected (Table 1 ) and tested against T47D and HDF. Neither of the samples affected the viability of T47D cells, but samples A2, A4, and A5 were highly cytotoxic to the HDF (Figure 2 ). At the lowest concentration (25 μg mL -1 ) the compounds reduced the HDF viability in a range from 56% (SD = 0; CC50 lower than 25 μg mL -1 , A2) to 73% (SD = 1; CC50 lower than 25 μg mL -1 , A5) ( Figure 2 ). Sample A1 was Then, the most active fractions were further separated and the samples with dominant components of the fractions were collected (Table 1 ) and tested against T47D and HDF. Neither of the samples affected the viability of T47D cells, but samples A 2 , A 4 , and A 5 were highly cytotoxic to the HDF (Figure 2 ). At the lowest concentration (25 µg mL −1 ) the compounds reduced the HDF viability in a range from 56% (SD = 0; CC 50 lower than 25 µg mL −1 , A 2 ) to 73% (SD = 1; CC 50 lower than 25 µg mL −1 , A 5 ) ( Figure 2 ). Sample A 1 was less active; however, the observed effects were dose-dependent. At the highest concentration (200 µg mL −1 ), it reduced the cell viability by 60% (SD = 1). Samples A 3 , A 6 , and A 8 did not affect the viability of HDF (toxicity below 15% at 200 µg mL −1 ) ( Figure 2 ). less active; however, the observed effects were dose-dependent. At the highest concentration (200 μg mL -1 ), it reduced the cell viability by 60% (SD = 1). Samples A3, A6, and A8 did not affect the viability of HDF (toxicity below 15% at 200 μg mL -1 ) ( Figure 2 ).

Effects of the isolated peptides (A3-A5 and A8) and samples containing a mixture of 2-3 peptides (A1, A2 and A6) from Pseudanabaena galeata CCNP1313 on the relative viability of the human dermal fibroblasts (HDF). The statistical analyses were performed using one-way ANOVA test. The significance is marked with * for p < 0.05; data are presented as mean values with standard deviation.

The antiviral activity of the P. galeata CCNP1313 cell extract was tested with the application of WNV, SARS-CoV-2, and HCoV-OC43. No cytopathic effects (CPE) were observed for HCT-8 cells infected with HCoV-OC43 and for Vero E6 cells infected with WNV. However, the extract was highly cytotoxic against Vero E6 cells infected with SARS-CoV-2. When the test was repeated with the extract roughly separated into four fractions (SPE F20-F80), the samples were not cytotoxic against Vero E6. Subsequently, reverse transcription (RT) and quantitative real-time PCR (RT-qPCR) were performed to assess the effect of the extract and SPE fractions on the viral RNA replication. The reduction in virus replication was expressed as a logarithmic reduction value (LRV) in the number of RNA copies in the infected cultures when compared to the untreated sample. The LRV for the tested viruses was equal to -1.7 (SD = 0.9) for WNV, -2.7 (SD = 0.7) for HCoV-OC43 (Figure S1), and from -0.3 (SD = 0.1) to -1.8 (SD = 0.3) for SARS-CoV-2 ( Figure S2 ).

Next, the potential antiviral activity of the thirty-one flash chromatography fractions obtained from the P. galeata CCNP1313 cell extract was tested using SARS-CoV-2 and A549 ACE2/TMPRSS2 cells. First, the CPE reduction by the fractions was assessed in a range of concentrations (1, 10, and 50 μg mL -1 ) (Table S2) . Four fractions (F40.4, F40.5, F60.3, and F60.6), applied at the highest concentration, were toxic to A549 ACE2/TMPRSS2 cells. No virusassociated CPE were observed for fractions F20.7, F80.1, and F80.3-80.5 at 50 μg mL -1 . Additionally, fractions F20.6-F40.2, F40.6-F60.2, F80.1-F.80.3, and F80.5-F80.6 showed weak or no CPE at 10 and 50 μg mL -1 . For these samples, the effects on SARS-CoV-2 replication were examined by RT-qPCR. Three fractions F80.4-F80.6 decreased the LRV in a dose-dependent manner, and, when applied at 100 μg mL -1 , they reduced LRV by 3-4 LOG10 ( Figure 3 ). Antiviral effects were also observed for fractions F40. Effects of the isolated peptides (A 3 -A 5 and A 8 ) and samples containing a mixture of 2-3 peptides (A 1 , A 2 and A 6 ) from Pseudanabaena galeata CCNP1313 on the relative viability of the human dermal fibroblasts (HDF). The statistical analyses were performed using one-way ANOVA test. The significance is marked with * for p < 0.05; data are presented as mean values with standard deviation.

The antiviral activity of the P. galeata CCNP1313 cell extract was tested with the application of WNV, SARS-CoV-2, and HCoV-OC43. No cytopathic effects (CPE) were observed for HCT-8 cells infected with HCoV-OC43 and for Vero E6 cells infected with WNV. However, the extract was highly cytotoxic against Vero E6 cells infected with SARS-CoV-2. When the test was repeated with the extract roughly separated into four fractions (SPE F20-F80), the samples were not cytotoxic against Vero E6. Subsequently, reverse transcription (RT) and quantitative real-time PCR (RT-qPCR) were performed to assess the effect of the extract and SPE fractions on the viral RNA replication. The reduction in virus replication was expressed as a logarithmic reduction value (LRV) in the number of RNA copies in the infected cultures when compared to the untreated sample. The LRV for the tested viruses was equal to -1.7 (SD = 0.9) for WNV, -2.7 (SD = 0.7) for HCoV-OC43 (Figure S1), and from -0.3 (SD = 0.1) to -1.8 (SD = 0.3) for SARS-CoV-2 ( Figure S2 ).

Next, the potential antiviral activity of the thirty-one flash chromatography fractions obtained from the P. galeata CCNP1313 cell extract was tested using SARS-CoV-2 and A549 ACE2/TMPRSS2 cells. First, the CPE reduction by the fractions was assessed in a range of concentrations (1, 10, and 50 µg mL −1 ) (Table S2) . Four fractions (F40.4, F40.5, F60.3, and F60.6), applied at the highest concentration, were toxic to A549 ACE2/TMPRSS2 cells. No virusassociated CPE were observed for fractions F20.7, F80.1, and F80.3-80.5 at 50 µg mL −1 . Additionally, fractions F20.6-F40.2, F40.6-F60.2, F80.1-F.80.3, and F80.5-F80.6 showed weak or no CPE at 10 and 50 µg mL −1 . For these samples, the effects on SARS-CoV-2 replication were examined by RT-qPCR. Three fractions F80.4-F80.6 decreased the LRV in a dose-dependent manner, and, when applied at 100 µg mL −1 , they reduced LRV by 3-4 LOG 10 ( Figure 3 ). Antiviral effects were also observed for fractions F40. In the case of isolated peptides (sample A3-A5 and A8) or samples containing a mixture of 2-3 petides (A1-A2, A6, and A7), a CPE reduction was recorded only for samples A2, A3, and A8 at 100 μg mL -1 (Table S3 ). These samples also had mild, but most significant effects on the SARS-CoV-2 replication (Sample A2 LRV = -0.7, SD = 0.3; Sample A3 LRV = -0.6, SD = 0.4; Sample A8 LRV = -0.6, SD = 0.3) (Figure 4 ). In the case of isolated peptides (sample A 3 -A 5 and A 8 ) or samples containing a mixture of 2-3 petides (A 1 -A 2 , A 6 , and A 7 ), a CPE reduction was recorded only for samples A 2 , A 3 , and A 8 at 100 µg mL −1 (Table S3 ). These samples also had mild, but most significant effects on the SARS-CoV-2 replication (Sample A 2 LRV = −0.7, SD = 0.3; Sample A 3 LRV = −0.6, SD = 0.4; Sample A 8 LRV = −0.6, SD = 0.3) ( Figure 4 ).

Next, selected samples (at 62.5 µg mL −1 in the case of fractions and at 50 µg mL −1 in the case of isolated peptides and samples containing 2-3 peptides) were screened for potential activities against the two main proteases of SARS-CoV-2, PL pro and M pro , which are the viral proteins often targeted by antivirals (Tables S4-S6 , Figures S3-S5 ). Fractions eluted with 80% MeOH (F80.2-F80.6) inhibited PL pro by more than 30%, with the most pronounced effects recorded for F80.5 (59%, SD = 7) (Table S4, Figure S3 ). The effects on M pro were milder, and only for F40.7, F80.1, F80.4, and F80.5 was the inhibition slightly greater than 20% (Table S5, Figure S4 ). In the case of peptides or samples containing a mixture of 2-3 peptides, the strongest inhibition of PL pro was observed for samples A 3 (43%, SD = 34) and A 4 (40%, SD = 21) (Table S6, Figure S5 ). Next, selected samples (at 62.5 μg mL -1 in the case of fractions and at 50 μg mL -1 in the case of isolated peptides and samples containing 2-3 peptides) were screened for potential activities against the two main proteases of SARS-CoV-2, PL pro and M pro , which are the viral proteins often targeted by antivirals (Tables S4-S6 , Figures S3-S5 ). Fractions eluted with 80% MeOH (F80.2-F80.6) inhibited PL pro by more than 30%, with the most pronounced effects recorded for F80.5 (59%, SD = 7) (Table S4, Figure S3 ). The effects on M pro were milder, and only for F40.7, F80.1, F80.4, and F80.5 was the inhibition slightly greater than 20% (Table S5, Figure S4 ). In the case of peptides or samples containing a mixture of 2-3 peptides, the strongest inhibition of PL pro was observed for samples A (43%, SD = 34) and A4 (40%, SD = 21) (Table S6, Figure S5 ).

In order to obtain sufficient amounts of material for bioassays, only the compounds present at the highest concentrations in the active fractions were isolated. Nontargeted LC-MS/MS analyses of the fractions revealed the presence of new peptides (Tables 2 and  S1 ). For fourteen of the compounds, a tentative structure was suggested. De novo struc- 

In order to obtain sufficient amounts of material for bioassays, only the compounds present at the highest concentrations in the active fractions were isolated. Nontargeted LC-MS/MS analyses of the fractions revealed the presence of new peptides (Tables 2 and S1). For fourteen of the compounds, a tentative structure was suggested. De novo structure elucidation was performed manually based on collision-induced dissociation (CID) mass spectra of the precursor peptides. The spectra were reproducible and contained a high number of ion peaks. The presence of specific amino acid residues was deduced based on the immonium ion peaks and the mass differences between the subsequent high-intensity b ions, usually accompanied by the a ions. The m/z values of the pseudomolecular ions of the detected peptides ranged from 500 to 1183. The peptides contained proteinogenic residues, mainly with nonpolar side chains: Ile/Leu, Ala, Val, Phe, Pro, and Gly. The Figures S6-S16 ). Because the applied method did not allow for discrimination between the isobaric ions of Leu and Ile, Leu * is used as a symbol of these residues. The structures of five of the compounds from samples A 1 , A 2 , A 5 , A 7 , and A 8 were not elucidated. However, the presence of characteristic immonium ions and differences between ion peaks allowed us to classify them as peptides. For the dereplication of tentatively identified structures, the CyanoMetDB database [24] was searched, but no matches were found. The detected peptides with at least two Ala residues, usually at the Nand C-termini, were marked as galeapeptins (GP), while Arg and Met-containing peptides were marked as PG (Pseudanabaena galeata peptides). The peptides with m/z values 677, 854, 862 and 890, for which we were not able to suggest structures are marked as UP (unknown peptide). 

Because the applied method did not allow for discrimination between the isobaric ions of Leu and Ile, Leu * is used as a symbol of these residues. 

Among the various bioactive cyanobacterial products, compounds cytotoxic to human cancer cells were reported most frequently [25, 26] . These compounds can cause inhibition of tubulin polymerization, microfilament disruption, caspase-3 activation, serine proteases inhibition or mitochondrial dysfunction, and oxidative damage [27, 28] . One of the most successful cyanobacterial metabolites, dolastatin-10, was used as a lead structure to develop anticancer antibody-drug conjugates. Some of the conjugates have already been approved for cancer treatment, while others are still in clinical trials [29, 30] . The antiviral activities of cyanometabolites were reported less frequently. Studies focused mainly on lectins, including cyanovirin-N (CV-N) and microvirin (MVN). These proteins bind with high affinity to oligomannose glycans of viral envelope glycoproteins gp120 [31, 32] . Other antiviral agents include polysaccharides [33] , peptides [34] , alkaloids [35] , and sulfoglycolipids [36] . Analyses of cyanobacterial metabolites performed with computational tools led to the identification of new potential antiviral agents. Deoxycylindrospermopsin showed the in silico potential to inhibit SARS-CoV-2 M pro and PL pro [35] , while phycocyanobilin, phycoerythrobilin, phycourocilin, and folic acid from Arthrospira were suggested to inhibit the virus replication by interaction with the spike protein (S-protein) [37] .

In the case of cytotoxic and antiviral activities, a significantly higher number of studies documented the effects of cyanobacterial extracts or fractionated samples than isolated metabolites with characterized structures [7, 21, 23, 37, 38] . Felczykowska et al. [23] analyzed several strains of Baltic cyanobacteria. They found that the extract from P. galeata CCNP1313 induced the death of the MCF-7 breast cancer cells by apoptosis, without necrotic changes or any effects on human dermal fibroblasts. Here, we showed that both the P. galeata CCNP1313 extract and fractions separated by the flash chromatography were active against another breast cancer cell line (T47D). As the most active fractions were separated by fractions with mild or no effects on T47D, it can be concluded that P. galeata CCNP1313 produces more than one metabolite with cytotoxic activity against breast cancer cells. Some of the active fractions also decreased HDF viability, but the trend in activity changes between the fractions was different to that in the case of T47D. This suggests that different agents are responsible for the activities against the two cell lines. Unfortunately, neither of the isolated peptides was found to be active in the MTT assays with T47D cells. Meanwhile, samples A 2 (GP655, GP818, and UP853), A 4 (PG725) and A 5 (UP890) ( Table 2 ) even at the lowest concentration (25 µg mL −1 ), reduced HDF viability by almost 60% (Figure 2 ). All isolated compounds present in the three active samples were also detected in the fractions F40.6-F60.4 (Table S1 ) for which a significant decrease in HDF viability was observed ( Figures 1B and 2) . As the extract from P. galeata CCNP1313 was inactive against HDF, the positive results for some fractions and compounds isolated from the extract might be confusing. One of the possible reasons may be antagonistic interactions in complex samples that mask the activity of individual compounds.

Strong effects of P. galeata CCNP1313 metabolites on viral replication were recorded in the case of coronaviruses HCoV-OC43 and SARS-CoV-2, and flavivirus WNV. Due to the unpredictability of their prevalence, infectious properties, and lack of effective therapeutic and preventive medicines, the threat of global infections caused by both types of viruses is constantly increasing [39, 40] . Since the emergence of coronavirus disease in 2019 (COVID-19) caused by SARS-CoV-2 [41] , the research on this family of pathogens has intensified. This is also the reason why, in the current work, further studies were focused on the activity of P. galeata CCNP1313 metabolites against SARS-CoV-2. For this purpose, the human lung epithelial cell line A549 ACE2/TMPRSS2 overexpressing the angiotensin-converting enzyme 2 (ACE2), and the transmembrane serine proteases TMPRSS2, crucial for the SARS-CoV-2 spike protein priming was used [42, 43] . A549 ACE2/TMPRSS2 cells recapitulate the natural route of entry for the coronavirus, which enters through fusion directly on the cell surface. As a result, this makes the virus independent of the endocytic machinery and cellular cathepsins [43] . Similarly to cytotoxic effects, the antiviral activity was recorded in fractions eluted with solvent of different MeOH content. They were separated by fractions that did not induce significant effects. This result, and the fact that only some of the fractions were active in both types of assays, indicate the production of several bioactive metabolites with selective activity against specific targets. A549 ACE2/TMPRSS2 cells infected with SARS-CoV-2 showed no or weak CPE when treated with fractions F40.2, F40.6-F60.2, and F80.3-F80.6 (Table S2 ). For the same fractions, the highest inhibition of viral replication was recorded. Furthermore, fractions F80.3-F80.6 showed the strongest inhibition of SARS-CoV-2 PL pro (Table S4, Figure S3 ). This papain-like protease encoded by the viral genome is one of the proteins that are essential for viral replication [44] . The protein also dysregulates the host immune sensing [45] . Small molecules, including FDA-approved drugs, have been extensively searched for their SARS PL pro inhibitory activity using high-throughput in vitro and in silico methods [44, 46, 47] . Although none of them has been approved yet, several PL pro inhibitors are currently in clinical trials, e.g., SPI-1005 (ClinicalTrials.gov Identifier: NCT04484025) and isotretinoin (ClinicalTrials.gov Identifier: NCT04361422).

Recognition of the biological activities of fractions containing a complex mixture of metabolites is just the first step, which should lead to the identification of the hits amongst P. galeata CCNP1313 metabolites. Therefore, in this study, the dominant components of the most active fractions were isolated and their activities were tested. The most profound CPE reduction and the concentration-dependent inhibition of viral replication were observed for sample A 2 containing GP655, GP818, and UP853; sample A 3 containing GP729 (136.9 µM); and sample A 8 containing GP1166 (85.7 µM) ( Figure 4 , Table S3 ). Based on the mass fragmentation spectra, four of the compounds (GP655, GP818, GP729, and GP1166) were classified to the same group of peptides. However, we were not able to elucidate the structure of GP1166. As this GP was also present in flash chromatography fractions showing some activity in antiviral assays (i.e., in F80.1-F80.3), this peptide may potentially be responsible for the observed effects.

Because no matches were found in the CyanoMetDB database [24] for the compounds detected in P. galeata CCNP1313 samples, they are considered new structures. None of them could also be classified as a new variant of the known peptides group commonly occurring in cyanobacterial taxa. So far, the only peptides identified in Pseudanabaena species were microcystins [13] [14] [15] [16] [17] [18] . Based on the analyses of MS/MS spectra it can be concluded that peptides detected in P. galeata CCNP1313 are composed of proteinogenic amino acids. In peptides with m/z 639 and 726 (named here PG638 and PG725), arginine and oxidized methionine were probably present. These two peptides have a similar structure and differ only in an additional Ser residue at the C-terminal part of PG725. The Met(O) present in the structure of these peptides can be an artefact formed in a nonenzymatic way during sample processing. It can also be a product of post-translational modifications generated by reactive oxygen species [48, 49] . Here, the former option seems more probable as low amounts of the Met-containing variant of PG725, i.e., PG709, were also present in the extract and chromatographic fractions ( Table 2, Table S1 ). In other compounds, mainly amino acids with hydrophobic side chains, such as those in Leu, Gly, Ala, Val, and Phe, were identified based on the immonium ions and mass differences in the MS/MS spectra.

Numerous peptides and peptide-like structures show a broad spectrum of biological activities. Generally, they are selective in their interactions with cellular targets, do not accumulate to toxic levels in organs, and can be easily synthesized or/and modified. Their therapeutic potential as anticancer peptides (ACPs) or antiviral peptides (AVPs) has been extensively explored, frequently with the application of computational screening techniques [46, [50] [51] [52] [53] . It was found that due to negatively charged components on the surface of the cancer cell, anticancer peptides should contain cationic amino acid residues (Lys or/and Arg) to facilitate the electrostatic interaction with the cell [54] . On the other hand, the hydrophobic parts of the peptides increase their membrane penetration capability. Therefore, in ACPs, Gly, Lys, and Leu were found to be the dominant components. The activity against cancer cells can also be enhanced by the presence of Pro, Phe, and Tyr [53, 55] . Hydrophobic residues and their modifications belong to the main components of several known anticancer cyanobacterial peptide-like structures such as dolastatin-10 [56] , apratoxins [57] , cryptophycins [58] , aurilides [59] , and belamide A [60] . Ala, Gly, Leu *, Phe, Pro, and Val also dominate in the structure of the peptides detected in P. galeata CCNP1313 samples. Although the isolated peptides did not affect T47D, the results obtained for one cancer cell line cannot eliminate the compounds from the list of potential ACPs. Peptides can also target viral or host proteins. In the case of the SARS-CoV-2 spike protein, specific residues of the receptor-binding domain can interact with AVPs, mainly through hydrogen bonding and, to a lesser degree, through hydrophobic and electrostatic interactions [51] . For these interactions, the presence of Tyr, Phe, Pro, Gly, Leu, Ala, Asn, Gln, and Cys were found to be the most important [51, 52] . Considering the above findings it can be speculated, that modification of P. galeata CCNP1313 peptide structures by the introduction of residues likely to form hydrogen bonds with the viral proteins could enhance the activity of the compounds. But even in their natural form, the isolated peptides possess some structural elements characteristic for both ACPs and AVPs, therefor the screening of their activity against a wider array of targets could shed more light on their pharmaceutical potential.

The studies conducted in this work and also the results previously published by Felczykowska et al. [23] proved the significance of P. galeata CCNP1313 as a source of potent cytotoxic and antiviral metabolites. Unfortunately, neither of the isolated peptides was found to be responsible for the cytotoxic activity against T47D. Some antiviral effects of the peptides were observed, but they were also weaker than that recorded for chromatographic fractions. It can be speculated that the bioactive metabolites produced by P. galeata CCNP1313 occur in minute amounts and/or were not detected with the applied LC-MS/MS method. The other option is that the observed effects resulted from interactions of several cell components present in complex samples and could not be restored in the case of single compounds.

P. galeata CCNP1313 (GenBank accession number MN273769) [7] was grown for biomass in BG11 medium, at room temperature (22 ± 1 • C), with constant illumination (20 µM photons m −2 s −1 ) and aeration [61] . The biomass from 5-L cultures was harvested in the exponential growth phase by centrifugation (4000× g; 15 min; 4 • C) and lyophilized (Martin Christ Gefriertrocknungsanlagen, Osterode am Harz, Germany).

The freeze-dried cyanobacterial material (2 g portions) was extracted twice with 75% methanol in MilliQ water (25 mL × 2) by vortexing (15 min) followed by bath sonication (2 min) and centrifugation (10,000× g; 15 min; 4 • C). The obtained supernatants were combined and diluted in MilliQ water so that the final MeOH concentration was reduced to less than 10%. The diluted extract was applied to a preconditioned 1 g Sep-Pak Vacc tC 18 cartridge (Waters, Milford, MA, USA) and the adsorbed substances were either eluted with 20 mL of 100% MeOH (crude extract) or with 20 mL of solvents composed of 20, 40, 60, and 80% MeOH in MilliQ water (SPE fractions). The eluates were evaporated to dryness in a centrifugal vacuum concentrator (MiVac, SP Scientific, Ipswich, UK) and tested in cytotoxicity and antiviral assays as extracts or SPE fractions.

To assess the activity of chromatographically separated fractions, 20 g of freeze-dried P. galeata CCNP1313 biomass was extracted twice with 500 mL of 75% MeOH as described above. The diluted extract was loaded onto a preconditioned 120 g SNAP KP-C 18 -HS flash chromatography column (Biotage, Uppsala, Sweden) using a Shimadzu HPLC system (Shimadzu Corporation, Kyoto, Japan) equipped with a photodiode array detector (PDA) and a fraction collector. A step gradient of aqueous MeOH (20-80%) was used to elute the sample components. For each of the steps of the chromatographic gradient, seven (20%-60% MeOH) or ten (80% MeOH) 40-mL fractions were collected (Table S1 ). Absorbance was measured at 210 and 280 nm and the flow rate was 20 mL min −1 . Portions (5-mL) of each fraction were taken and concentrated in a centrifugal vacuum concentrator for two hours and then lyophilized.

From selected fractions collected during flash chromatography (Table 3) the dominant components were isolated by further fractionation using the same HPLC system but different columns ( Table 3 ). The mobile phase was composed of 5% acetonitrile in MilliQ water (A) and 100% acetonitrile (B) both with 0.1% formic acid. The conditions of three preparative chromatography runs (Prep1-Prep3) are shown in Table 3 . The components of the samples containing isolated peptides or a mixture of 2-3 peptides were characterized based on their mass fragmentation spectra (Table 1) . Before the assays, the samples were vacuum concentrator and lyophilized. 

At each step of extraction and fractionation, the contents of the samples were analyzed using a hybrid triple quadrupole/linear ion trap mass spectrometer (QTRAP5500, Applied Biosystems, Sciex, Concord, ON, Canada) coupled with an Agilent 1200 (Agilent Technologies, Waldboronn, Germany) HPLC system. The analyses were performed in a positive ion electrospray scanning mode, using a Zorbax Eclipse XDB-C 18 column (4.6 × 150 mm; 5 µm) (Agilent Technologies, Santa Clara, CA, USA) and the same mobile phase as in preparative chromatography [61] . Spectra within the range of m/z of 500-1000 Da, and with signal intensity greater than 500,000 cps, were collected at a collision energy of 50 V. The results were processed using Analyst QS (Version 1.7.1, Applied Biosystems/MDS Analytical Technologies, Concord, ON, Canada, 2019).

The evaluation of the cytotoxicity of P. galeata CCNP1313 was carried out in three steps. In the first step, the activity of the extract (200 µg mL −1 ) against T47D and HDF was analyzed. In the second step, the activities of thirty-one flash chromatography fractions (200 µg mL −1 ), were tested against T47D and HDF (both cell lines from the European Collection of Authenticated Cell Cultures (ECACC); Merck KGaA, Darmstadt, Germany). In the final step, the activities of samples A 1 -A 6 and A 8 (25-200 µg mL −1 ) against both cell lines were tested. MTT assays were performed according to Felczykowska et al. [23] . In summary, T47D cells were seeded in RPMI1640 medium (Carl Roth GmbH, Karlsruhe, Germany). HDF cells were seeded in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA). Both media were supplemented with fetal bovine serum (10% v/v; Merck KGaA, Darmstadt, Germany) and penicillin-streptomycin solution (50 U and 50 µg mL −1 ; Merck KGaA, Darmstadt, Germany). In the tests, the cells were seeded at 1 × 10 4 cells per well and at each step of the test incubated at 37 • C, 5% CO 2 . The cytotoxicity of fractions dissolved in 1% DMSO was measured after incubation (24 h) with the application of a microplate reader (Spectramax i3, Molecular Devices, LLC., San Jose, CA, USA). Cell viability was calculated as the ratio of the mean absorbance value for the three replicates containing the samples to the mean absorbance of the three replicates of the corresponding solvent control and expressed as a percentage with standard deviation. Data were analyzed using the Student t-test or one-way ANOVA test when applicable.

As in the case of cytotoxicity assays, the activities of extract, flash chromatography fractions and samples A 1 -A 8 were analyzed.

Cell Culture. Vero E6 (ATCC: CRL-1586), HCT-8 (ATCC: CCL-244), primary human dermal fibroblasts, A549 (ATCC: CCL-185; ATCC, Manassas, VA, USA) overexpressing ACE2 and TMPRSS2 (A549 ACE2/TMPRSS2 in-house generated [43] ) were maintained in DMEM medium (Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA) supplemented with 5% v/v heat-inactivated fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific Inc., Waltham, MA, USA) and penicillin-streptomycin solution (100 U mL −1 and 100 µg mL −1 , respectively) (PAN Biotech GmbH, Aidenbach, Bayern, Germany). Medium for A549 ACE2/TMPRSS2 cells was additionally supplemented with blasticidin S (10 µg mL −1 ; Sigma-Aldrich, Merck, Warsaw, Poland) and puromycin (0.5 µg mL −1 ; Sigma-Aldrich, Merck, Warsaw, Poland).

Cytotoxicity Assays. The XTT Cell Viability Assay Kit (Biological Industries, Cromwell, CT, USA) was used according to the manufacturer's instructions. Briefly, cells were incubated with samples at different concentrations (10-250 µg mL −1 ) for 48-120 h at 37 • C, 5% CO 2 (Table 4 ). After incubation, the medium was discarded and fresh medium was overlaid on the cells, along with the activated 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-(2H)-tetrazolium-5-carboxanilide (XTT) solution and the cells were incubated for 2 h (37 • C, 5% CO 2 ). The absorbance was measured using a microplate reader (Tecan Infinite M200; Tecan Group Ltd., Männedorf, Switzerland). Only extracts exhibiting low cytotoxicity (the viability of the treated >80% compared to the untreated samples) were further analyzed. Cytopathic Effects Assessment. The cytopathic effects were assessed with the application of a light microscope (Evos Fluorescent Microscope, Thermo Fisher Scientific Inc., Waltham, MA, USA) 96-h post-infection (p.i.).

Virus Replication Inhibition Assays. Cells were preincubated with different concentrations of the samples (2 h, 37 • C, 5% CO 2 ; Table 4 ). The virus infection was then performed in the presence of the samples (Table 4) . After 2 h, cells were rinsed twice with PBS and a fresh medium with another portion of the tested samples was added. After 48-120 h infection (Table 4 ) the CPE caused by the virus in the cell monolayer was evaluated, and the culture supernatants were collected for RT-qPCR analyses of viral replication.

RNA Isolation and RT-qPCR. The isolation of viral RNA was carried out using a commercially available RNA isolation kit (Viral DNA/RNA Isolation Kit; A&A Biotechnology, Gdańsk, Poland), according to the protocol provided by the manufacturer. The isolated RNA was subjected to RT-qPCR using the GoTaq ® Probe 1-Step RT-qPCR System Protocol kit (Promega, Madison, WI, USA) according to the manufacturer's instructions with the use of primers and probes (Genomed, Warsaw, Poland) listed in Table 5 . Appropriate standards were prepared to evaluate the number of viral RNA molecules in the samples. The reaction was carried out in a thermal cycler (CFX96 Touch Real-197 Time PCR Detection System; Bio-Rad, Hercules, CA, USA). The obtained data are presented as LRV, showing the relative decrease in the amount of virus in the cell culture media compared to the untreated sample. Data were analyzed using the nonparametric Mann-Whitney or Kruskal-Wallis tests when applicable. Table 5 . Oligonucleotides used in RT-qPCR.

Oligonucleotides Sequence ( Inhibition of SARS-CoV-2 proteases. In the assays, the following reagents were used: M pro and PL pro from in-house production [62, 63] For the assay, the protein solution (10 µL) was first loaded onto a low-volume white 96-well plate and incubated for 1 h at room temperature with 0.2 µL of inhibitors solution.

The experiment was carried out in duplicate. The enzymatic reaction was started by adding 10 µL of substrate equipped with 7-amino-4-methylcoumarin (AMC) fluorophore at a final concentration of 50 µM and 2 µM, respectively. Enzymatic activity was assessed determining the changes in the fluorescence, using Tecan M200 Pro (Tecan Group Ltd., Männedorf, Switzerland). The signal was measured at 360/460 nm excitation/emission wavelengths for 90 min with 60 s intervals and with 2 s orbital shaking after each measurement. Data analyses were performed using Mathematica 12 (Wolfram, Oxfordshire, UK).

The percentage of inhibition was calculated as a fraction of the initial velocity of the M/PL pro control according to the formula: 100% − initial velocity with inhibitor initial velocity M/PLpro control The initial velocities were calculated by fitting a straight line into datapoints from 20 to 30 using a script in Mathematica12 software. Enzymatic assays were validated using well-known PL pro (GRL0617 (IC 50 : 2.1 µM) [64] ) and M pro inhibitors (PF-07321332, commercial name-nirmatrelvir (IC 50 : 19.2 nM), ClinicalTrials.gov Identifier: NCT05263908) ( Figure S17 ).

The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/toxins14050330/s1. Table S1 : The content of the Pseudanabaena galeata CCNP1313 flash chromatography fractions. Figure Table S6 : The effects of isolated peptides and samples containing a mixture of 2-3 peptides from Pseudanabaena galeata CCNP1313 on the activity of SARS-CoV-2 PL Pro protease. Data are presented as mean values with standard deviation. Figure S5 : The effects of isolated peptides and samples containing a mixture of 2-3 peptides from Pseudanabaena galeata CCNP1313 on the activity of SARS-CoV-2 PL Pro protease. Figure S6 : Enhanced product ion mass spectrum of galeapeptin GP598 with the proposed structure Ala-Leu *-Val-Leu *-Leu *-Ala, characterized based on the following ion peaks at m/z 599 [M + H] + , 129 Arg immonium ion, 120 Phe immonium ion, 86 Leu * immonium ion. Figure S8 : Enhanced product ion mass spectrum of the galeapeptin GP655 with the proposed structure Ala-Leu *-Val-Leu *-Leu *-Ala-Gly, characterized based on the following ion peaks at m/z 656 [M + H] 

(Pro + Ala + Val + Leu * + Ala) − H 2 O − CO] + , 353 [Ala + Pro + Val + Leu * + H − CO] + , 268 [Ala + Pro + Val + H] + , 169 [Ala + Pro + H] + , 141 [Ala + Pro + H − CO] + , 120 Phe immonium ion, 86 Leu * immonium ion. Figure S16: Enhanced product ion mass spectrum of galeapeptin GP998 with the proposed structure Ala-Pro-Val-Leu *-Ala-Phe-Val-Val-Leu *-Ala, characterized based on the following ion peaks at m/z 999

120 Phe immonium ion, 86 Leu * immonium ion, 72 Val immonium ion. Figure S17: Positive controls and IC 50 values determination for enzymatic assays (A) M pro (IC 50 for PF-07321332 a well-known M pro inhibitor, commercial name nirmatrelvir with reported literature IC 50 value of 19.2 nM) and (B) PL pro

Taxonomic classification of Cyanoprokaryotes (cyanobacterial genera) 2014, using a polyphasic approach

Eds.) AlgaeBase; World-Wide Electronic Publication

Cyanobacteria in hot springs of East Africa and their potential toxicity

Algal community dynamics and halotolerance in a terrestrial, hypersaline environment

Cyanoprokaryota and algae of Arctic terrestrial ecosystems in the Hornsund area

Trophic state, phytoplankton assemblages and limnological diagnosis of the Castanhão reservoir, CE, Brazil

Baltic cyanobacteria-A source of biologically active compounds

Biodiversity and toxin production of cyanobacteria in mangrove swamps in the Red Sea off the southern coast of Saudi Arabia

Polyphasic characterization of four species of Pseudanabaena (Oscillatoriales, cyanobacteria) from China and insights into polyphyletic divergence within the Pseudanabaena genus

Cyanobacterial diversity in the soil of Russian dry steppes and semideserts. Microbiology

Toxic effects of Pseudanabaena tenuis (Cyanobacteria) on the cladocerans Daphnia magna and Ceriodaphnia dubia

Chemoecological screening reveals high bioactivity in diverse culturable Portuguese marine cyanobacteria

Isolation, characterization and quantification of microcystins (heptapeptides hepatotoxins) in Microcystis aeruginosa dominated bloom of Lalla Takerkoust lakereservoir (Morocco)

Detection and quantification of microcystins from cyanobacteria strains isolated from reservoirs and ponds in Morocco

Analyses of microcystins in the biomass of Pseudanabaena limnetica collected in Znojmo reservoir

Taxonomic diversity and toxicological assessment of cyanobacteria in Moroccan inland waters

Cyanotoxins from black band disease of corals and from other coral reef environments

Toxic effects of extracts from Pseudanabaena galeata (Cyanoprokaryota) in mice and cell cultures in vitro

Antiviral activity of cultured blue-green algae (Cyanophyta)

Phycobiliproteins from Pseudanabaena tenuis rich in c-phycoerythrin protect against HgCl 2 -caused oxidative stress and cellular damage in the kidney

Exploring bioactive properties of marine cyanobacteria isolated from the Portuguese coast: High potential as a source of anticancer compounds

Antidiabetic screening of some Indonesian marine cyanobacteria collection

Selective inhibition of cancer cells' proliferation by compounds included in extracts from Baltic Sea cyanobacteria

CyanoMetDB, a comprehensive public database of secondary metabolites from cyanobacteria

Natural product biosynthetic diversity and comparative genomics of the cyanobacteria

Natural products from cyanobacteria: Focus on beneficial activities

Marine cyanobacteria compounds with anticancer properties: A review on the implication of apoptosis

Biological targets and mechanisms of action of natural products from marine cyanobacteria

Discovery and development of dolastatin 10-derived antibody drug conjugate anticancer drugs

Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody-drug conjugation

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans

An update of the recombinant protein expression systems of cyanovirin-N and challenges of preclinical development

Calcium spirulan derived from Spirulina platensis inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis

Cyclic depsipeptides, ichthyopeptins A and B, from Microcystis ichthyoblabe

Cyanobacterial metabolites as promising drug leads against the M pro and PL pro of SARS-CoV-2: An in silico analysis

The inhibition of the reverse transcriptase of HIV-1 by the natural sulfoglycolipids from cyanobacteria: Contribution of different moieties to their high potency

Uncovering the bioactive potential of a cyanobacterial natural products library aided by untargeted metabolomics

Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2

The continued threat of emerging flaviviruses

The emergence, genomic diversity and global spread of SARS-CoV-2

The 2019-2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Identification of cellular factors required for SARS-CoV-2 replication

Deubiquitinating enzymes in coronaviruses and possible therapeutic opportunities for COVID-19

In silico exploration of inhibitors for SARS-CoV-2 s papain-like protease

High-throughput screening identifies established drugs as SARS-CoV-2 PL pro inhibitors

Characterization of methionine oxidation and methionine sulfoxide reduction using methionine-rich cysteine-free proteins

Methionine oxidation and reduction in proteins

Unraveling the bioactivity of anticancer peptides as deduced from machine learning

Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2

Antiviral peptides as promising therapeutics against SARS-CoV-2

Identification of subtypes of anticancer peptides based on sequential features and physicochemical properties

Pro-apoptotic cationic host defense peptides rich in lysine or arginine to reverse drug resistance by disrupting tumor cell membrane

Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)

The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10

Apratoxin H and apratoxin A sulfoxide from the Red Sea cyanobacterium Moorea producens

Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. Strain GSV 224

Structure-activity relationship study on odoamide: Insights into the bioactivities of aurilide-family hybrid peptide-polyketides

Characteristics of cyanobacterium Pseudanabaena galeata CCNP1313 from the Baltic Sea

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

Institutional Review Board Statement: Not applicable.

Data Availability Statement: Not applicable.

The authors declare no conflict of interest.